Immunotherapy of hepatocellular carcinoma: Is there a place for regulatory T-lymphocyte depletion?

Immunotherapy

Volumn 3, Issue 4 SUPPL., 2011, Pages 32-34

  Cany, Jeannette ^a   Tran, Lucile ^a   Gauttier, Vanessa ^a   Judor, Jean Paul ^a   Vassaux, Georges ^a   Ferry, Nicolas ^a   Conchon, Sophie ^a  

^a HÔTEL DIEU   (France)

Author keywords

fetoprotein; hepatocellular carcinoma; immunotherapy; liver; regulatory T lymphocyte

Indexed keywords

ALPHA FETOPROTEIN; CANCER VACCINE; ICA 614; PC 61; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CD25+ T LYMPHOCYTE; CONTROLLED STUDY; DNA VECTOR; IMMUNIZATION; IMMUNOTHERAPY; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T CELL DEPLETION; TUMOR IMMUNITY; TUMOR VOLUME;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; CARCINOMA, HEPATOCELLULAR; DIETHYLNITROSAMINE; GENETIC VECTORS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; LIVER NEOPLASMS; LYMPHOCYTE DEPLETION; MICE; T-LYMPHOCYTES, REGULATORY; TUMOR BURDEN;

EID: 79955615251     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/imt.11.29     Document Type: Article

References (17)

1. El-Serag HB, Marrero JA, Rudolph L, Reddy KR: Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 134(6), 1752-1763 (2008). (Pubitemid 351615415)
2. Llovet JM, Bruix J: Novel advancements in the management of hepatocellular carcinoma in 2008. J. Hepatol. 48(Suppl. 1), S20-S37 (2008).
3. Zerbini A, Pilli M, Ferrari C, Missale G: Is there a role for immunotherapy in hepatocellular carcinoma? Dig. Liver Dis. 38(4), 221-225 (2006). (Pubitemid 44356180)
4. Sung CH, Hu CP, Hsu HC et al.: Expression of class I and class II major histocompatibility antigens on human hepatocellular carcinoma. J. Clin. Invest. 83(2), 421-429 (1989).
5. Butterfield LH, Ribas A, Dissette VB et al.: A Phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four a-fetoprotein peptides. Clin. Cancer Res. 12(9), 2817-2825 (2006).
6. Pichard V, Royer PJ, Richou C et al.: Detection, isolation, and characterization of a-fetoprotein-specific T cell populations and clones using MHC class I multimer magnetic sorting. J. Immunother. 31(3), 246-253 (2008). (Pubitemid 351441006)
7. Zerbini A, Pilli M, Penna A et al.: Radiofrequency thermal ablation of hepatocellular carcinoma liver nodules can activate and enhance tumor-specific T-cell responses. Cancer Res. 66(2), 1139-1146 (2006). (Pubitemid 43165983)
8. Gao Q, Qiu SJ, Fan J et al.: Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection. J. Clin. Oncol. 25(18), 2586-2593 (2007). (Pubitemid 47041232)
9. Fu J, Xu D, Liu Z et al.: Increased regulatory T cells correlate with CD8 T-cell impairment and poor survival in hepatocellular carcinoma patients. Gastroenterology 132(7), 2328-2339 (2007). (Pubitemid 46890865)
10. Greten TF, Manns MP, Korangy F: Immunotherapy of hepatocellular carcinoma. J. Hepatol. 45(6), 868-878 (2006). (Pubitemid 44646691)
11. Takayama T, Sekine T, Makuuchi M et al.: Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial. Lancet 356(9232), 802-807 (2000).
12. Kuang M, Peng BG, Lu MD et al.: Phase II randomized trial of autologous formalin-fixed tumor vaccine for postsurgical recurrence of hepatocellular carcinoma. Clin. Cancer Res. 10(5), 1574-1579 (2004). (Pubitemid 38435545)
13. Cany J, Avril A, Pichard V, Aubert D, Ferry N, Conchon S: A transgenic mouse with b-galactosidase as a fetal liver self-antigen for immunotherapy studies. J. Hepatol. 47(3), 396-403 (2007). (Pubitemid 47189605)
14. McIlroy D, Barteau B, Cany J et al.: DNA/amphiphilic block copolymer nanospheres promote low-dose DNA vaccination. Mol. Ther. 17(8), 1473-1481 (2009).
15. Cany J, Barteau B, Tran L et al.: AFP-specific immunotherapy impairs growth of autochthonous hepatocellular carcinoma in mice. J. Hepatol. 54(1), 115-121 (2011).
16. Shimizu J, Yamazaki S, Sakaguchi S: Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J. Immunol. 163(10), 5211-5218 (1999).
17. Greten TF, Ormandy LA, Fikuart A et al.: Low-dose cyclophosphamide treatment impairs regulatory T cells and unmasks AFP-specific CD4+ T-cell responses in patients with advanced HCC. J. Immunother. 33(2), 211-218 (2010).